Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2023 | Futility analysis in clinical trials: practical and ethical considerations

Suzanne Hendrix • 21 Mar 2023
AD/PD 2023
Alzheimer’s Disease Dementia

Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, shares some insights into the value of futility analysis and how this may benefit patients enrolled in clinical trials. While futility analysis can be helpful, Dr Hendrix highlights the importance of setting strict boundaries and being cautious when declaring futility, especially in the case of Alzheimer’s disease. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Suzanne Hendrix

Efficient use of open label extension data
1:31
Efficient use of open label extension data
Suzanne Hendrix • 19 Jul 2023
Time saved with Alzheimer’s disease therapeutics
4:29
Time saved with Alzheimer’s disease therapeutics
Suzanne Hendrix • 19 Jul 2023
Time saved in Alzheimer’s disease in Phase III trial of donanemab
0:49
Time saved in Alzheimer’s disease in Phase III trial of donanemab
Suzanne Hendrix • 19 Jul 2023
Measuring cognitive impairment in early Alzheimer’s disease
1:16
Measuring cognitive impairment in early Alzheimer’s disease
Suzanne Hendrix • 19 Jul 2023

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals